Month: January 2020

Arcutis Announces Exercise of Option for Exclusive License to Highly Selective JAK1 Inhibitor for All Topical Dermatological Uses in U.S., Canada, Europe and Japan

ARQ-252 potential to offer "Best in Class" topical JAK therapy Phase 2b study in adult patients with hand eczema anticipated...

error: Content is protected !!